Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RTA 408 0.5%, 1%, 3% · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part A | PLACEBO_COMPARATOR | RTA 408 lotion 0.5%, 1%, and 3% and lotion vehicle applied to skin twice daily for 14 days |
| Part B | EXPERIMENTAL | Up to 3% RTA 408 lotion applied to skin twice daily for 14 days (% concentration to be determined, based on results from Part A, \~100 cm2 surface area) |
| Part C | EXPERIMENTAL | 3% RTA 408 lotion applied to skin twice daily for 28 days (\~500 cm2 surface area) |
| Name | Type | Description |
|---|---|---|
| RTA 408 Lotion 0.5%, 1%, 3% | DRUG | - |
| Lotion vehicle/placebo | DRUG | - |
Inclusion Criteria: 1. Subjects must voluntarily give written informed consent and agree to comply with visit schedule including willingness to remain at the study site; 2. Subjects must be adults (male or female), ages 18 to 65, inclusive; 3. Subjects must have healthy skin on which reddening can ...
RTA 408 0.5%, 1%, 3% is an investigational small molecule lotion developed by Biogen Inc. (BIIB). It is a topical formulation evaluated in a Phase 1 clinical trial in healthy volunteers. The specific therapeutic indication for this lotion has not been disclosed.
RTA 408 0.5%, 1%, 3% is being developed by Biogen Inc., which trades on the Nasdaq under the ticker BIIB. Biogen is the company responsible for the clinical program of this investigational topical lotion.
RTA 408 0.5%, 1%, 3% is in Phase 1 clinical development. The program includes one completed Phase 1 trial. It is an investigational product and has not been approved by the FDA for any indication.
RTA 408 0.5%, 1%, 3% has been studied in one Phase 1 clinical trial, NCT02029716, titled "RTA 408 Lotion in Healthy Volunteers." This completed trial enrolled 109 healthy adult participants in the United States and used a randomized, double-blind, placebo-controlled design.
Yes, RTA 408 0.5%, 1%, 3% is also known as RTA 408 Lotion 0.5%, 1%, 3%. Both names refer to the same investigational topical lotion developed by Biogen Inc. (BIIB) and studied in the Phase 1 trial NCT02029716.